Literature DB >> 10754286

Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells.

X D Zhang1, A V Franco, T Nguyen, C P Gray, P Hersey.   

Abstract

Induction of apoptosis in cells by TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF family, is believed to be regulated by expression of two death-inducing and two inhibitory (decoy) receptors on the cell surface. In previous studies we found no correlation between expression of decoy receptors and susceptibility of human melanoma cells to TRAIL-induced apoptosis. In view of this, we studied the localization of the receptors in melanoma cells by confocal microscopy to better understand their function. We show that the death receptors TRAIL-R1 and R2 are located in the trans-Golgi network, whereas the inhibitory receptors TRAIL-R3 and -R4 are located in the nucleus. After exposure to TRAIL, TRAIL-R1 and -R2 are internalized into endosomes, whereas TRAIL-R3 and -R4 undergo relocation from the nucleus to the cytoplasm and cell membranes. This movement of decoy receptors was dependent on signals from TRAIL-R1 and -R2, as shown by blocking experiments with Abs to TRAIL-R1 and -R2. The location of TRAIL-R1, -R3, and -R4 in melanoma cells transfected with cDNA for these receptors was similar to that in nontransfected cells. Transfection of TRAIL-R3 and -R4 increased resistance of the melanoma lines to TRAIL-induced apoptosis even in melanoma lines that naturally expressed these receptors. These results indicate that abnormalities in "decoy" receptor location or function may contribute to sensitivity of melanoma to TRAIL-induced apoptosis and suggest that further studies are needed on the functional significance of their nuclear location and TRAIL-induced movement within cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10754286     DOI: 10.4049/jimmunol.164.8.3961

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL.

Authors:  Jennifer S Carew; Steffan T Nawrocki; Yelena V Krupnik; Kenneth Dunner; David J McConkey; Michael J Keating; Peng Huang
Journal:  Blood       Date:  2005-09-06       Impact factor: 22.113

2.  Constitutional promoter methylation and risk of familial melanoma.

Authors:  Paula L Hyland; Laura S Burke; Ruth M Pfeiffer; Melissa Rotunno; David Sun; Prasad Patil; Xiaolin Wu; Margaret A Tucker; Alisa M Goldstein; Xiaohong Rose Yang
Journal:  Epigenetics       Date:  2014-02-13       Impact factor: 4.528

3.  From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis.

Authors:  Aikaterini F Giannopoulou; Athanassios D Velentzas; Athanasios K Anagnostopoulos; Adamantia Agalou; Nikos C Papandreou; Stamatia A Katarachia; Dimitra G Koumoundourou; Eumorphia G Konstantakou; Vasiliki I Pantazopoulou; Anastasios Delis; Maria T Michailidi; Dimitrios Valakos; Dimitris Chatzopoulos; Popi Syntichaki; Vassiliki A Iconomidou; Ourania E Tsitsilonis; Issidora S Papassideri; Gerassimos E Voutsinas; Polydefkis Hatzopoulos; Dimitris Thanos; Dimitris Beis; Ema Anastasiadou; George Th Tsangaris; Dimitrios J Stravopodis
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

4.  Resistance to Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus type 1-infected T-cell lines.

Authors:  Takehiro Matsuda; Alex Almasan; Mariko Tomita; Jun-nosuke Uchihara; Masato Masuda; Kazuiku Ohshiro; Nobuyuki Takasu; Hideo Yagita; Takao Ohta; Naoki Mori
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Osteoprotegerin (OPG) and related proteins (RANK, RANKL and TRAIL) in thyroid disease.

Authors:  Sumit K Sood; Sabapathy Balasubramanian; Sue Higham; Malee Fernando; Barney Harrison
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

6.  Detachment of esophageal carcinoma cells from extracellular matrix causes relocalization of death receptor 5 and apoptosis.

Authors:  Guang-Chao Liu; Jun Zhang; Shi-Gui Liu; Rong Gao; Zhang-Fu Long; Ke Tao; Yuan-Fang Ma
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

7.  Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression.

Authors:  Vladimir N Ivanov; Tom K Hei
Journal:  Exp Cell Res       Date:  2006-09-28       Impact factor: 3.905

Review 8.  TNF superfamily: a growing saga of kidney injury modulators.

Authors:  Maria D Sanchez-Niño; Alberto Benito-Martin; Sara Gonçalves; Ana B Sanz; Alvaro C Ucero; Maria C Izquierdo; Adrian M Ramos; Sergio Berzal; Rafael Selgas; Marta Ruiz-Ortega; Jesus Egido; Alberto Ortiz
Journal:  Mediators Inflamm       Date:  2010-10-04       Impact factor: 4.711

9.  c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance.

Authors:  Jae J Song; Miroslaw Jerzy Szczepanski; So Young Kim; Joo-Hang Kim; Jee Young An; Yong Tae Kwon; Marco A Alcala; David L Bartlett; Yong J Lee
Journal:  Cell Signal       Date:  2010-03       Impact factor: 4.315

10.  Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma.

Authors:  Agatha Labrinidis; Peter Diamond; Sally Martin; Shelley Hay; Vasilios Liapis; Irene Zinonos; Natalie A Sims; Gerald J Atkins; Cristina Vincent; Vladimir Ponomarev; David M Findlay; Andrew C W Zannettino; Andreas Evdokiou
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.